Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2009

View Archived Issues

Teva submits BLA to FDA for XM-02 for chemotherapy-induced neutropenia

Kalbitor approved in U.S. for hereditary angioedema

Plethora Solutions and Columbia Laboratories execute marketing agreement for Striant SR

Acacia's subsidiary enters into license agreement with Boston Scientific

Ardea Biosciences reports results from combination trial of RDEA-594 and febuxostat

Pfizer and Astellas launch Caduet combination tablets in Japan

Sitaxentan reduces post-CPB acute kidney injury in porcine model

Phase III data reported for ticagrelor vs. clopidogrel in platelet aggregation

MK-1775 exhibits synergism with gemcitabine in pancreatic tumors in vivo

TRIN-2755 exhibits antitumor activity in multiple xenograft mouse models

Interim data presented from AV-412 phase I trial in advanced solid tumors

Data from phase I study on AS-703569 disclosed at 2009 AACR-NCI-EORTC meeting

Takeda reports results from first half of 2009 ended September 30

Merck KGaA describes TGF-beta receptor inhibitors as oncolytics

Advinus Therapeutics discloses novel adenosine receptor antagonists

Biovitrum discovers novel GPR119 agonists for the treatment of obesity

Novel antibacterial agents presented by Actelion

Keryx Biopharmaceuticals' perifosine receives FDA fast track designation

FDA lifts clinical hold of CytRx's arimoclomol in amyotrophic lateral sclerosis

DermaGen's antimicrobial peptide successful in phase I/IIa clinical trials in atopic dermatitis

GlaxoSmithKline files for approval of Rotarix vaccine in Japan

EMEA accepts clinical development plan for DiaPep-277

Vasopharm recruits first patient in a phase IIa trial of VAS-203

TiGenix completes acquisition of Orthomimetics

Wilex receives preliminary results of phase III Redectane trial

Hemispherx Biopharma receives FDA complete response letter for Ampligen NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...